Cargando…
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy
BACKGROUND & AIMS: We evaluated the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in difficult-to-treat PWIDs with presumed high risk for non-adherence to antiviral therapy using an innovative concept involving their opioid agonist therapy (OAT) facility. METHODS: N = 221 patients (m/f: 168/...
Autores principales: | Schmidbauer, Caroline, Schwarz, Michael, Schütz, Angelika, Schubert, Raphael, Schwanke, Cornelia, Gutic, Enisa, Pirker, Roxana, Lang, Tobias, Reiberger, Thomas, Haltmayer, Hans, Gschwantler, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177501/ https://www.ncbi.nlm.nih.gov/pubmed/34086708 http://dx.doi.org/10.1371/journal.pone.0252274 |
Ejemplares similares
-
Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs—First real world data from Austria
por: Schmidbauer, Caroline, et al.
Publicado: (2020) -
Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy
por: Schwarz, M., et al.
Publicado: (2023) -
CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers
por: Schwarz, Caroline, et al.
Publicado: (2023) -
Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019) -
Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
por: Shin, Hyun Phil
Publicado: (2023)